Leqembi sales inch higher; Spark’s pivot leads to layoffs
Bio Pharma Dive
JULY 12, 2024
Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site.
Bio Pharma Dive
JULY 12, 2024
Sales data suggest forecasts for the Alzheimer’s drug may be in reach. Elsewhere, Ipsen is licensing an ADC and Novartis is closing a San Diego site.
Pharmaceutical Technology
MARCH 2, 2023
Merck has reported an increase in group net sales by 12.9% The growth in sales was driven by all regions and business sectors, particularly Life Science. in group sales in fiscal 2022. Additionally, due to the acquisition of Exelead, a biopharmaceutical contract development and manufacturing company, sales increased by 0.4%.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
JANUARY 2, 2023
South Korean biotechnology company Alteogen has signed an exclusive license agreement with Swiss company Sandoz to develop and market biosimilar products that are enabled by the former’s Hybrozyme technology. Additionally, the company will have an option to license Alteogen’s Hybrozyme technology for two more products.
Pharmaceutical Technology
MAY 3, 2023
Tay Therapeutics, a spin-off firm from the University of Dundee in the UK, has signed a licensing deal with VYNE Therapeutics for the development of its oral bromodomain and extra-terminal domain (BET) inhibitor as a possible treatment for immune-inflammatory and fibrotic disorders.
Pharmaceutical Technology
DECEMBER 8, 2022
The therapy’s sales and promotion works in Japan following the transfer of marketing authorisation will be carried out by the Kite Cell Therapy Business Unit at Gilead Sciences K.K. The post Kite and Daiichi Sankyo update cell therapy licensing agreement appeared first on Pharmaceutical Technology.
Pharmaceutical Technology
APRIL 13, 2023
Biogen has exercised an option to license Denali Therapeutics ’ (Denali) programme to develop immunotherapies for the treatment of Alzheimer’s disease. Denali is also expected to receive potential development and commercial milestone payments upon achieving certain milestones, along with royalties based on the future net sales of the drug.
Pharmaceutical Technology
DECEMBER 5, 2022
Women’s healthcare company TherapeuticsMD has sign ed agreements for licensing its products to the Mayne Pharma affiliate in the US. Additionally, TherapeuticsMD will grant Mayne the exclusive license to market Annovera in the US. TherapeuticsMD will also get a 20-year royalty stream linked to Mayne’s net product sales.
Let's personalize your content